Thomas Martens1, Roy W Beck2, Ryan Bailey2, Katrina J Ruedy2, Peter Calhoun2, Anne L Peters3, Rodica Pop-Busui4, Athena Philis-Tsimikas5, Shichun Bao6, Guillermo Umpierrez7, Georgia Davis7, Davida Kruger8, Anuj Bhargava9, Laura Young10, Janet B McGill11, Grazia Aleppo12, Quang T Nguyen13, Ian Orozco14, William Biggs15, K Jean Lucas16, William H Polonsky17, John B Buse10, David Price18, Richard M Bergenstal19. 1. International Diabetes Center, Park Nicollet Internal Medicine, Minneapolis, Minnesota. 2. Jaeb Center for Health Research, Tampa, Florida. 3. Keck School of Medicine of the University of Southern California, Los Angeles. 4. University of Michigan, Ann Arbor. 5. Scripps Whittier Diabetes Institute, San Diego, California. 6. Vanderbilt University Medical Center, Nashville, Tennessee. 7. Emory University School of Medicine, Atlanta, Georgia. 8. Henry Ford Health System, Detroit, Michigan. 9. Iowa Diabetes Research, West Des Moines. 10. University of North Carolina School of Medicine, Chapel Hill. 11. Washington University School of Medicine, St Louis, Missouri. 12. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 13. Las Vegas Endocrinology, Henderson, Nevada. 14. Carteret Medical Group, Morehead City, North Carolina. 15. Amarillo Medical Specialists, Amarillo, Texas. 16. Diabetes & Endocrinology Consultants PC, Morehead City, North Carolina. 17. Behavioral Diabetes Institute, San Diego, California. 18. Dexcom Inc, San Diego, California. 19. International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota.
Abstract
Importance: Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. Objective: To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. Design, Setting, and Participants: This randomized clinical trial was conducted at 15 centers in the US (enrollment from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. Interventions: Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). Main Outcomes and Measures: The primary outcome was hemoglobin A1c (HbA1c) level at 8 months. Key secondary outcomes were CGM-measured time in target glucose range of 70 to 180 mg/dL, time with glucose level at greater than 250 mg/dL, and mean glucose level at 8 months. Results: Among 175 randomized participants (mean [SD] age, 57 [9] years; 88 women [50%]; 92 racial/ethnic minority individuals [53%]; mean [SD] baseline HbA1c level, 9.1% [0.9%]), 165 (94%) completed the trial. Mean HbA1c level decreased from 9.1% at baseline to 8.0% at 8 months in the CGM group and from 9.0% to 8.4% in the BGM group (adjusted difference, -0.4% [95% CI, -0.8% to -0.1%]; P = .02). In the CGM group, compared with the BGM group, the mean percentage of CGM-measured time in the target glucose range of 70 to 180 mg/dL was 59% vs 43% (adjusted difference, 15% [95% CI, 8% to 23%]; P < .001), the mean percentage of time at greater than 250 mg/dL was 11% vs 27% (adjusted difference, -16% [95% CI, -21% to -11%]; P < .001), and the means of the mean glucose values were 179 mg/dL vs 206 mg/dL (adjusted difference, -26 mg/dL [95% CI, -41 to -12]; P < .001). Severe hypoglycemic events occurred in 1 participant (1%) in the CGM group and in 1 (2%) in the BGM group. Conclusions and Relevance: Among adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin, continuous glucose monitoring, as compared with blood glucose meter monitoring, resulted in significantly lower HbA1c levels at 8 months. Trial Registration: ClinicalTrials.gov Identifier: NCT03566693.
Importance: Continuous glucose monitoring (CGM) has been shown to be beneficial for adults with type 2 diabetes using intensive insulin therapy, but its use in type 2 diabetes treated with basal insulin without prandial insulin has not been well studied. Objective: To determine the effectiveness of CGM in adults with type 2 diabetes treated with basal insulin without prandial insulin in primary care practices. Design, Setting, and Participants: This randomized clinical trial was conducted at 15 centers in the US (enrollment from July 30, 2018, to October 30, 2019; follow-up completed July 7, 2020) and included adults with type 2 diabetes receiving their diabetes care from a primary care clinician and treated with 1 or 2 daily injections of long- or intermediate-acting basal insulin without prandial insulin, with or without noninsulin glucose-lowering medications. Interventions: Random assignment 2:1 to CGM (n = 116) or traditional blood glucose meter (BGM) monitoring (n = 59). Main Outcomes and Measures: The primary outcome was hemoglobin A1c (HbA1c) level at 8 months. Key secondary outcomes were CGM-measured time in target glucose range of 70 to 180 mg/dL, time with glucose level at greater than 250 mg/dL, and mean glucose level at 8 months. Results: Among 175 randomized participants (mean [SD] age, 57 [9] years; 88 women [50%]; 92 racial/ethnic minority individuals [53%]; mean [SD] baseline HbA1c level, 9.1% [0.9%]), 165 (94%) completed the trial. Mean HbA1c level decreased from 9.1% at baseline to 8.0% at 8 months in the CGM group and from 9.0% to 8.4% in the BGM group (adjusted difference, -0.4% [95% CI, -0.8% to -0.1%]; P = .02). In the CGM group, compared with the BGM group, the mean percentage of CGM-measured time in the target glucose range of 70 to 180 mg/dL was 59% vs 43% (adjusted difference, 15% [95% CI, 8% to 23%]; P < .001), the mean percentage of time at greater than 250 mg/dL was 11% vs 27% (adjusted difference, -16% [95% CI, -21% to -11%]; P < .001), and the means of the mean glucose values were 179 mg/dL vs 206 mg/dL (adjusted difference, -26 mg/dL [95% CI, -41 to -12]; P < .001). Severe hypoglycemic events occurred in 1 participant (1%) in the CGM group and in 1 (2%) in the BGM group. Conclusions and Relevance: Among adults with poorly controlled type 2 diabetes treated with basal insulin without prandial insulin, continuous glucose monitoring, as compared with blood glucose meter monitoring, resulted in significantly lower HbA1c levels at 8 months. Trial Registration: ClinicalTrials.gov Identifier: NCT03566693.
Authors: Roy W Beck; Laura E Bocchino; John W Lum; Craig Kollman; Victoria Barnes-Lomen; Mark Sulik; Michael J Haller; Bruce Bode; Joseph T Cernich; Anthony A Killeen; Uttam Garg; David Liljenquist; Janey G Adams; Margaret Clements; Deanna Gabrielson; Terri Johnson; Mark A Clements Journal: Diabetes Technol Ther Date: 2021-04-07 Impact factor: 6.118
Authors: Roy W Beck; Tonya Riddlesworth; Katrina Ruedy; Andrew Ahmann; Richard Bergenstal; Stacie Haller; Craig Kollman; Davida Kruger; Janet B McGill; William Polonsky; Elena Toschi; Howard Wolpert; David Price Journal: JAMA Date: 2017-01-24 Impact factor: 56.272
Authors: Glen H Murata; Jayendra H Shah; Richard M Hoffman; Christopher S Wendel; Karen D Adam; Patricia A Solvas; Syed U Bokhari; William C Duckworth Journal: Diabetes Care Date: 2003-06 Impact factor: 19.112
Authors: Thomas Danne; Revital Nimri; Tadej Battelino; Richard M Bergenstal; Kelly L Close; J Hans DeVries; Satish Garg; Lutz Heinemann; Irl Hirsch; Stephanie A Amiel; Roy Beck; Emanuele Bosi; Bruce Buckingham; Claudio Cobelli; Eyal Dassau; Francis J Doyle; Simon Heller; Roman Hovorka; Weiping Jia; Tim Jones; Olga Kordonouri; Boris Kovatchev; Aaron Kowalski; Lori Laffel; David Maahs; Helen R Murphy; Kirsten Nørgaard; Christopher G Parkin; Eric Renard; Banshi Saboo; Mauro Scharf; William V Tamborlane; Stuart A Weinzimer; Moshe Phillip Journal: Diabetes Care Date: 2017-12 Impact factor: 19.112
Authors: Anne Peters; Nathan Cohen; Peter Calhoun; Katrina J Ruedy; Roy W Beck; Thomas W Martens; Shichun Bao; Nelly M Njeru; Stayce E Beck; David A Price Journal: Diabetes Obes Metab Date: 2020-11-17 Impact factor: 6.577
Authors: Melanie J Davies; Vanita R Aroda; Billy S Collins; Robert A Gabbay; Jennifer Green; Nisa M Maruthur; Sylvia E Rosas; Stefano Del Prato; Chantal Mathieu; Geltrude Mingrone; Peter Rossing; Tsvetalina Tankova; Apostolos Tsapas; John B Buse Journal: Diabetologia Date: 2022-09-24 Impact factor: 10.460
Authors: Rodolfo J Galindo; Mohammed K Ali; Shealeigh A Funni; Andrew B Dodge; Shaheen S Kurani; Nilay D Shah; Guillermo E Umpierrez; Rozalina G McCoy Journal: Diabetes Care Date: 2022-01-01 Impact factor: 17.152
Authors: Satish K Garg; Mark Kipnes; Kristin Castorino; Timothy S Bailey; Halis Kaan Akturk; John B Welsh; Mark P Christiansen; Andrew K Balo; Sue A Brown; Jennifer L Reid; Stayce E Beck Journal: Diabetes Technol Ther Date: 2022-02-21 Impact factor: 7.337
Authors: Andrew J Karter; Melissa M Parker; Howard H Moffet; Lisa K Gilliam; Richard Dlott Journal: Diabetes Technol Ther Date: 2022-02-18 Impact factor: 7.337